Amgen is a global biotechnology leader with more than 45 years of experience developing, manufacturing and delivering innovative biologics and biosimilar medicines. The company is led by executives Robert Bradway, Chairman and CEO; Murdo Gordon, Executive Vice President, Amgen Global Markets and Policy; and Paul Burton, Senior Vice President and Chief Medical Officer. The Biosimilars Business Unit is led by Marc Doble, Vice President and General Manager.

Amgen entered the biosimilars arena in 2011 following passage of the Biologics Price Competition and Innovation Act, drawing on decades of biologics innovation and manufacturing expertise. Since then, Amgen has invested more than $2 billion across its portfolio of 11 approved or in-development biosimilar medicines, focusing primarily on oncology, inflammation and rare diseases, while expanding into new therapeutic areas like ophthalmology (see approved product table). Amgen’s biosimilars portfolio continues to deliver results, generating more than $13 billion in sales worldwide as of the first quarter of 2026.

Looking ahead, the company has reiterated its commitment to further invest in biosimilars, aiming to reach more than $4 billion in annual biosimilar sales by 2030.

As a top U.S.-headquartered biosimilar manufacturer, Amgen stands out in the field by fully integrating its innovative biologics and biosimilars teams and facilities, allowing its biosimilars to benefit from the same world-class scientific expertise, rigorous quality systems and reliable supply network that support its innovative medicines. Advances in Amgen’s end-to-end manufacturing have further strengthened the company’s biosimilar capabilities; its technologies are more precise, more quantitative and more advanced than ever before, enhancing Amgen’s ability to deliver high-quality, reliable biosimilars that align with real-world patient needs.

Amgen believes the marketplace with biosimilars is in a critical phase where long-term growth and sustainability rely on policies that: foster a stable, predictable environment for developing and delivering biosimilars; uphold rigorous, science-based regulatory standards; and promote marketplace competition between biosimilars and originator biologics.

Why you may be hearing more about Amgen:

Guided by the needs of patients and informed by the company’s experience in innovative oncology treatments, Amgen is investigating new immuno-oncology biosimilars to OPDIVO^® (nivolumab) (ABP 206) and KEYTRUDA^® (pembrolizumab) (ABP 234). In addition, Amgen is investigating a biosimilar (ABP 692) to the top-selling CD20 antibody OCREVUS^® (ocrelizumab) for multiple sclerosis.

Alongside announcing recent manufacturing expansions across facilities in Ohio and North Carolina, Amgen is investing more than $600 million in a new state-of-the-art Science & Innovation Center at its headquarters in Thousand Oaks, California. The new center will bring researchers, engineers and manufacturing teams together to advance the development and delivery of biological medicines, including biosimilars.

As Amgen advances its biosimilars pipeline, the company sees a clear opportunity to strengthen the marketplace with biosimilars by encouraging reliable choice across therapeutic areas and supporting long-term value for healthcare systems. A robust and competitive marketplace has the potential to ease cost pressures for patients, providers and payers. By investing in high-quality biosimilar development, Amgen is helping to create a more sustainable environment that delivers meaningful savings today while supporting future innovation across the healthcare ecosystem.